ReviewCell communication and signaling : CCS2025
The gut-heart axis: a correlation between Paneth cells' dysfunction, microbiome dysbiosis, and cardiovascular diseases.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting the Gut-Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers.International journal of molecular sciences · 2026Review
- Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications.Journal of nanobiotechnology · 2026Review
- Gut Microbiota Alterations in Heart Failure Patients: Insights from a Systematic Review.Journal of clinical medicine · 2025Review
- Targeting the Gut Microbiota in Pediatric Obesity: A Paradigm Shift in Prevention and Treatment? A Comprehensive Review.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiota dysbiosis is characterized by an imbalance in the core microbial equilibrium, leading to changes in the homeostasis of the gastrointestinal tract (GIT) environment. As guardians of the gut microbiota, Paneth cells (PCs) secrete antimicrobial peptides (AMPs) and play a crucial role in maintaining gut integrity and innate immunity in the small intestine. The gut-heart axis has emerged as a critical mediator in cardiovascular disease (CVD) pathogenesis and has drawn significant attention. In this regard, the reciprocal relationship between gut dysbiosis and PC dysfunction has been proposed, which may contribute to a compromised gut barrier and increased systemic inflammation, one of the main drivers of CVD development. It is also well-established that dysfunctional PCs disrupt gut homeostasis and subsequently permit the translocation of pro-inflammatory metabolites like trimethylamine N-oxide (TMAO) while reducing protective short-chain fatty acids (SCFAs), which correlates with atherosclerosis, hypertension, and heart failure.A better understanding of the underlying mechanisms linking gut health, PCs function, and cardiovascular outcomes is warranted for developing novel gut-target therapies against major CVD risks. This review aimed to comprehensively discuss the predominant role of PCs in the gut-heart axis, some effective compounds on PC function and AMP modulation, and finally, a possible correlation between PC dysfunction and CVD pathogenesis, encouraging future research to further elucidate this crosstalk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.